MedPage Today -- ATLANTA -- When added to optimal medical therapy, aliskiren (Tekturna), a direct renin inhibitor, did not improve outcomes for patients who had had a myocardial infarction accompanied by left ventricular dysfunction, a randomized, placebo-controlled trial showed.
